First Trust Advisors
CYCN icon

First Trust Advisors’s Cyclerion Therapeutics CYCN Stock Holding History

First Trust Advisors’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,586
Closed -$187K – 2349
2020
Q2 		$187K Buy
1,586
+127
+9% +$10.6K ﹤0.01% 2268
2020
Q1 		$77K Sell
1,459
-283
-16% -$20.2K ﹤0.01% 2311
2019
Q4 		$95K Sell
1,742
-31
-2% -$2.9K ﹤0.01% 2363
2019
Q3 		$430K Buy
+1,773
New +$383K ﹤0.01% 2178

Other funds holding CYCN

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors's CYCN Position: Q3 2020 in Review

First Trust Advisors sold out of Cyclerion Therapeutics (CYCN) in Q3 2020, closing a stake of 1,586 shares — an estimated $187K sold.

First Trust Advisors first reported a position in CYCN in Q3 2019 and held it in 4 quarters. The position peaked at $430K in Q3 2019. 73 funds tracked by Wall St. Rank hold CYCN as of Q3 2020.

  • First Trust Advisors reported no remaining Cyclerion Therapeutics position as of Q3 2020 after selling out during the quarter.
  • First Trust Advisors sold 1,586 Cyclerion Therapeutics shares in Q3 2020, an estimated $187K.
  • First Trust Advisors first reported a position in Cyclerion Therapeutics in Q3 2019 and held it in 4 quarters.
  • First Trust Advisors's Cyclerion Therapeutics position peaked at $430K in Q3 2019.
  • 73 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q3 2020.

Based on First Trust Advisors's 13F filing for Q3 2020, filed 5 Nov 2020.